March 2015

New Product - Abilify Maintena

Abilify Maintena (aripiprazole) is an atypical antipsychotic. It has been proposed that its efficacy in schizophrenia is mediated through a combination of partial agonism at dopamine D₂ and serotonin 5-HT_1A receptors and antagonism at serotonin 5-HT_2A receptors. Abilify Maintena is indicated in the maintenance of clinical improvement in the treatment of schizophrenia. It is available as 300 mg or 400 mg powder for prolonged release suspension for injection in a one month convenience kit.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au